Open AccessSunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response
Author(s) -
Astrid A.M. van der Veldt,
Martijn R. Meijerink,
Alfons J.M. van den Eertwegh,
Axel Bex,
Gijsbert de Gast,
John B.A.G. Haanen,
Epie Boven
Publication year - 2008
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-07-4089
Subject(s) - sunitinib , medicine , nephrectomy , renal cell carcinoma , primary tumor , response evaluation criteria in solid tumors , cancer , progressive disease , kidney cancer , refractory (planetary science) , oncology , radiology , urology , kidney , metastasis , disease , physics , astrobiology
Nephrectomy before immunotherapy in patients with metastatic renal cell cancer (RCC) will improve patient outcome. In addition, the primary tumor is known to be refractory to cytokines. Sunitinib is now approved for treatment of advanced RCC, but its effect on the primary tumor has yet to be reported.